Cymabay Therapeutics Story

Cymabay Therapeutics Inc -- USA Stock  

USD 13.53  0.08  0.59%

Macroaxis does not monitor all media channels or aggregates social signals for Cymabay Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Cymabay Therapeutics Inc, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Cymabay Therapeutics. Check also Cymabay Therapeutics Hype Analysis, Cymabay Therapeutics Correlation and Cymabay Therapeutics Performance
Trading Sheet Reviewing the Levels for Cymabay Therapeutics, Inc.
Cymabay Therapeutics, Inc. presently has an EV or Enterprise Value of 291551. The EV helps show how the market assigns value to a company as a whole.

Read More...   

Story Momentum

This media report from distributed on December 7, 2017 was a factor to the next trading day price appreciation.The overall trading delta against the next closing price was 0.73% . The overall trading delta when the story was published against the current closing price is 59.61% .

Similar stores for Cymabay Therapeutics

Taking an Obtrusive Look into Cymabay Therapeutics s Technicalsnews
Dunbar StandardFull coverage
over a month ago at 
Sale by Kurt Emster of 162979 shares of Cymabay Therapeutics
Filed transaction by Cymabay Therapeutics Inc director. General open market or private sale of non-derivative or derivative security
over two months ago at 
Analyst Advice And Earnings Insight Marvell Technology Group Ltd. MRVL ...
The recently concluded session had traders exchanging Marvell Technology Group Ltd. high level. Roughly 9.4 million shares changed hands compared to the three-month volume average 8.64 million shares.
over three months ago at 
CymaBay Therapeutics Rating Reiterated by Leerink Swann
CymaBay Therapeutics Inc logo Leerink Swann reiterated their buy rating on shares of CymaBay Therapeutics in a report published on Tuesday, November 28th. Trading Focus Eyeing Shares of Cymabay Therapeutics, Inc. and ... - Aiken Advocate CymaBay Therapeutics Getting Somewhat Positive Press Coverage, Analysis ... - StockNewsTimes

Did you try this?

Run Bollinger Bands Now

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
Hide  View All  NextLaunch Bollinger Bands

Retained Earnings

Retained Earnings Comparative Analysis
  Retained Earnings 
      Cymabay Therapeutics Comparables 
Cymabay Therapeutics is currently under evaluation in retained earnings category among related companies. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.